Does the media favor NBIX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 13 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.18 beat Neurocrine Biosciences' score of 0.55 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BIIB or NBIX?

In the previous week, Biogen had 14 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 27 mentions for Biogen and 13 mentions for Neurocrine Biosciences. Biogen's average media sentiment score of 0.94 beat Neurocrine Biosciences' score of 0.55 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 12 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NBIX or UTHR?

In the previous week, United Therapeutics had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.86 beat Neurocrine Biosciences' score of 0.55 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NBIX or INCY?

In the previous week, Incyte had 24 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 37 mentions for Incyte and 13 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 0.57 beat Neurocrine Biosciences' score of 0.55 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 16 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer NBIX or EXEL?

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 13 articles in the media. Exelixis' average media sentiment score of 1.24 beat Neurocrine Biosciences' score of 0.55 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neurocrine Biosciences (NBIX) Competitors

$159.76 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$162.34 +2.58 (+1.61%)

As of 06/12/2026 07:59 PM Eastern

Compare

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

Should you buy Neurocrine Biosciences stock or one of its competitors? MarketBeat compares Neurocrine Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Neurocrine Biosciences presently has a consensus price target of $187.52, suggesting a potential upside of 17.38%. Alnylam Pharmaceuticals has a consensus price target of $463.13, suggesting a potential upside of 63.74%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Neurocrine Biosciences has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62
Alnylam Pharmaceuticals	$3.71B	10.17	$313.75M	$3.66	77.28

Neurocrine Biosciences has a net margin of 21.55% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 13 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.18 beat Neurocrine Biosciences' score of 0.55 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Neurocrine Biosciences on 9 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Biogen?

Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Neurocrine Biosciences has a net margin of 21.55% compared to Biogen's net margin of 13.81%. Neurocrine Biosciences' return on equity of 19.79% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Biogen has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.99	$1.29B	$9.32	21.46
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62

87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biogen currently has a consensus price target of $217.26, suggesting a potential upside of 8.60%. Neurocrine Biosciences has a consensus price target of $187.52, suggesting a potential upside of 17.38%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	12 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.55
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Biogen had 14 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 27 mentions for Biogen and 13 mentions for Neurocrine Biosciences. Biogen's average media sentiment score of 0.94 beat Neurocrine Biosciences' score of 0.55 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	12 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Biogen on 11 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to United Therapeutics?

Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, United Therapeutics had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.86 beat Neurocrine Biosciences' score of 0.55 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neurocrine Biosciences currently has a consensus price target of $187.52, indicating a potential upside of 17.38%. United Therapeutics has a consensus price target of $619.42, indicating a potential upside of 13.45%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Neurocrine Biosciences is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62
United Therapeutics	$3.18B	7.28	$1.33B	$27.09	20.15

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Incyte?

Neurocrine Biosciences (NASDAQ:NBIX) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Incyte had 24 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 37 mentions for Incyte and 13 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 0.57 beat Neurocrine Biosciences' score of 0.55 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	16 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Neurocrine Biosciences currently has a consensus price target of $187.52, suggesting a potential upside of 17.38%. Incyte has a consensus price target of $105.10, suggesting a potential downside of 3.16%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Neurocrine Biosciences is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62
Incyte	$5.14B	4.22	$1.29B	$7.08	15.33

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 21.55%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Incyte	26.71%	26.66%	19.77%

Summary

Incyte beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Exelixis?

Neurocrine Biosciences (NASDAQ:NBIX) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Exelixis has lower revenue, but higher earnings than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62
Exelixis	$2.32B	5.76	$782.57M	$3.01	17.65

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Exelixis	35.08%	39.89%	30.23%

Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Neurocrine Biosciences presently has a consensus price target of $187.52, suggesting a potential upside of 17.38%. Exelixis has a consensus price target of $47.35, suggesting a potential downside of 10.87%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 13 articles in the media. Exelixis' average media sentiment score of 1.24 beat Neurocrine Biosciences' score of 0.55 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Exelixis on 8 of the 15 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBIX vs. The Competition

Export

Metric	Neurocrine Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.06B	$3.01B	$6.74B	$12.07B
Dividend Yield	N/A	1.76%	2.67%	5.67%
P/E Ratio	24.62	18.84	24.21	24.42
Price / Sales	5.62	309.12	512.04	109.94
Price / Cash	31.87	55.88	27.48	37.92
Price / Book	4.90	3.98	10.66	6.83
Net Income	$478.60M	$75.79M	$3.57B	$337.67M
7 Day Performance	-2.06%	1.57%	0.58%	1.17%
1 Month Performance	0.85%	-0.73%	1.54%	3.16%
1 Year Performance	28.43%	23.44%	25.40%	30.58%

Neurocrine Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBIX Neurocrine Biosciences	3.8299 of 5 stars	$159.76 flat	$187.52 +17.4%	+28.4%	$16.06B	$2.86B	24.62	2,000	Insider Trade
ALNY Alnylam Pharmaceuticals	4.6319 of 5 stars	$292.16 -3.6%	$463.13 +58.5%	-8.2%	$40.46B	$3.71B	79.83	2,770	News Coverage Positive News Analyst Upgrade
BIIB Biogen	3.5719 of 5 stars	$192.62 -1.4%	$217.26 +12.8%	+53.1%	$28.84B	$9.89B	20.67	7,500
UTHR United Therapeutics	4.2007 of 5 stars	$544.69 -0.9%	$619.42 +13.7%	+92.7%	$23.34B	$3.18B	20.11	1,400	Insider Trade
INCY Incyte	2.8214 of 5 stars	$100.64 -1.7%	$104.85 +4.2%	+60.2%	$20.45B	$5.14B	14.21	2,844	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Summary

How does Neurocrine Biosciences compare to Biogen?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Summary

How does Neurocrine Biosciences compare to Incyte?

Summary

How does Neurocrine Biosciences compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Do analysts prefer NBIX or ALNY?

Which has more volatility and risk, NBIX or ALNY?

Which has preferable valuation and earnings, NBIX or ALNY?

Is NBIX or ALNY more profitable?

Do institutionals & insiders have more ownership in NBIX or ALNY?

Does the media favor NBIX or ALNY?

Summary

How does Neurocrine Biosciences compare to Biogen?

Is BIIB or NBIX more profitable?

Which has more risk and volatility, BIIB or NBIX?

Which has preferable earnings and valuation, BIIB or NBIX?

Do insiders and institutionals hold more shares of BIIB or NBIX?

Do analysts prefer BIIB or NBIX?

Does the media refer more to BIIB or NBIX?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Which has more volatility & risk, NBIX or UTHR?

Does the media prefer NBIX or UTHR?

Do insiders & institutionals hold more shares of NBIX or UTHR?

Do analysts rate NBIX or UTHR?

Which has better earnings and valuation, NBIX or UTHR?

Is NBIX or UTHR more profitable?

Summary

How does Neurocrine Biosciences compare to Incyte?

Does the media prefer NBIX or INCY?

Do analysts prefer NBIX or INCY?

Which has better valuation & earnings, NBIX or INCY?

Do institutionals and insiders hold more shares of NBIX or INCY?

Which has more risk & volatility, NBIX or INCY?

Is NBIX or INCY more profitable?

Summary

How does Neurocrine Biosciences compare to Exelixis?

Which has preferable valuation & earnings, NBIX or EXEL?

Is NBIX or EXEL more profitable?

Which has more risk & volatility, NBIX or EXEL?

Do analysts prefer NBIX or EXEL?

Do insiders & institutionals hold more shares of NBIX or EXEL?

Does the media prefer NBIX or EXEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools